PeptideJournal
Peptide Profiles25 min read

Hexarelin: Potent GHRP Research Profile

Hexarelin represents one of the most powerful growth hormone-releasing peptides ever synthesized. Among the family of GHRPs, it stands out for triggering GH pulses up to three times larger than GHRH itself—but with an important caveat: its receptors desensitize faster than any other peptide in its

Hexarelin represents one of the most powerful growth hormone-releasing peptides ever synthesized. Among the family of GHRPs, it stands out for triggering GH pulses up to three times larger than GHRH itself—but with an important caveat: its receptors desensitize faster than any other peptide in its class.

What makes hexarelin particularly interesting isn't just its GH-releasing potency. Unlike other growth hormone secretagogues, hexarelin binds to two distinct receptors: the familiar ghrelin receptor (GHS-R1a) and the less-known CD36 scavenger receptor found primarily in cardiac tissue. This dual-receptor activity gives hexarelin cardioprotective properties that work independently of growth hormone—a finding that's shifted research attention from its endocrine effects to its cardiovascular applications.

But hexarelin's story is also one of unrealized clinical potential. Despite reaching Phase II trials for growth hormone deficiency and heart failure in the 1990s and early 2000s, it never made it to market. The reasons include receptor desensitization, elevations in cortisol and prolactin at higher doses, and the emergence of safer alternatives. Today, hexarelin remains a research compound—one that offers valuable insights into growth hormone physiology and cardiac protection, but carries regulatory restrictions that limit its use outside controlled studies.

Table of Contents

  1. Quick Facts
  2. What Is Hexarelin?
  3. Mechanisms of Action
  4. Research Evidence
  5. Comparison with Other GHRPs
  6. Safety Profile and Side Effects
  7. Legal and Regulatory Status
  8. Frequently Asked Questions
  9. Bottom Line
  10. References

Quick Facts

PropertyDetails
Full NameHexarelin (Examorelin)
Peptide TypeGrowth hormone-releasing peptide (GHRP)
Amino Acid SequenceHis-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂
Molecular Weight887.04 Da
Molecular FormulaC₄₇H₅₈N₁₂O₆
CAS Number140703-51-1
Receptor TargetsGHS-R1a (ghrelin receptor), CD36 scavenger receptor
Half-LifeApproximately 55-75 minutes (varies by species and context)
FDA StatusNot approved for human therapeutic use
WADA StatusProhibited substance (S2 category)

What Is Hexarelin?

Hexarelin is a synthetic hexapeptide—a six-amino-acid chain—designed to stimulate growth hormone release from the pituitary gland. It belongs to the growth hormone secretagogue (GHS) family, specifically the subset known as growth hormone-releasing peptides (GHRPs). These compounds mimic the action of ghrelin, the body's natural "hunger hormone," by activating the growth hormone secretagogue receptor.

Developed in the 1990s as part of research into non-GHRH-based GH stimulation, hexarelin was engineered to be potent and resistant to enzymatic breakdown. Its structure includes D-amino acids (D-2-methyltryptophan and D-phenylalanine), which prevent rapid degradation by peptidases and boost its pharmacological activity.

What sets hexarelin apart from other GHRPs is twofold:

  1. Exceptional GH-releasing potency: In clinical studies, intravenous hexarelin at doses of just 0.5 to 2.0 μg/kg triggered peak GH levels of 52-55 ng/mL—substantially higher than the 19.8 μg/L typically seen with GHRH administration.

  2. CD36 receptor binding: Beyond the ghrelin receptor, hexarelin also binds to CD36, a scavenger receptor abundant in cardiac tissue. This interaction mediates cardioprotective effects that occur independently of growth hormone release.

Hexarelin progressed to Phase II clinical trials for growth hormone deficiency and congestive heart failure but was never brought to market. Its clinical development stalled due to concerns about receptor desensitization, hormonal side effects, and the availability of alternative therapies. Today, hexarelin is used exclusively in research settings.

Mechanisms of Action

Hexarelin's biological activity involves multiple pathways, with effects that extend beyond simple GH stimulation. Its dual-receptor binding pattern makes it one of the more mechanistically complex peptides in the GHRP class.

Growth Hormone Secretagogue Receptor (GHS-R1a) Activation

Hexarelin's primary mechanism involves binding to the GHS-R1a receptor—the same G-protein-coupled receptor activated by ghrelin. Upon binding, hexarelin triggers a signaling cascade involving:

  • Phospholipase C (PLC) activation: This produces inositol 1,4,5-triphosphate (IP₃), which increases intracellular calcium.
  • Calcium influx: The calcium surge stimulates somatotrophs in the anterior pituitary to release stored GH.

Hexarelin works synergistically with GHRH. When given together, the two compounds produce GH release far exceeding either agent alone. This synergy occurs because GHRH stimulates cAMP-dependent pathways while hexarelin activates calcium-dependent mechanisms—two complementary routes to GH secretion.

Research indicates three potential mechanisms for hexarelin's GH-releasing action:

  1. Direct pituitary action: Hexarelin can act directly on pituitary somatotrophs, though this appears to be a minor contributor.
  2. GHRH release: In adult rats, hexarelin stimulates hypothalamic GHRH secretion, which then triggers pituitary GH release.
  3. Unknown hypothalamic factor: Evidence suggests hexarelin may release another, yet-unidentified hypothalamic factor that amplifies GH secretion.

Unlike GHRH, hexarelin is more resistant to the inhibitory effects of somatostatin, glucose, and free fatty acids—factors that normally suppress GH release. This resistance may contribute to its exceptional potency.

CD36 Scavenger Receptor Activation

The discovery that hexarelin binds to CD36 was a turning point in understanding its non-endocrine effects. CD36 is a class B scavenger receptor expressed in cardiomyocytes, endothelial cells, macrophages, and adipocytes. It plays roles in fatty acid uptake, lipid metabolism, inflammation, and cardiovascular function.

Using photoaffinity labeling, researchers identified that hexarelin binds to a specific region of CD36—the Asn132-Glu177 sequence with Met169 as the contact point. This binding site overlaps with the receptor's binding domain for oxidized low-density lipoprotein (oxLDL), suggesting hexarelin might interfere with lipid uptake processes relevant to atherosclerosis.

Activation of cardiac CD36 by hexarelin results in:

  • Cardioprotection during ischemia-reperfusion injury: Hexarelin reduces infarct size and preserves cardiac function following myocardial ischemia.
  • Anti-apoptotic signaling: Hexarelin inhibits cardiomyocyte apoptosis induced by angiotensin II, doxorubicin, and oxidative stress.
  • Increased coronary perfusion: In perfused hearts, hexarelin increases coronary perfusion pressure in a dose-dependent manner, an effect absent in CD36-deficient mice.

These cardiac effects occur independently of GH, as demonstrated in hypophysectomized rats where hexarelin still protected against ischemia-reperfusion damage.

Metabolic Signaling Through PPARγ

Hexarelin influences metabolism through activation of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor that regulates adipocyte differentiation, insulin sensitivity, and lipid metabolism. Research in insulin-resistant mice showed that hexarelin treatment:

The mechanism likely involves hexarelin binding to CD36, which then activates PPARγ signaling pathways that improve lipid handling and insulin sensitivity.

Neuroprotective Pathways

In the central nervous system, hexarelin activates the PI3K/Akt pathway, which provides neuroprotection through:

  • Regulation of intracellular calcium homeostasis
  • Modulation of nitric oxide synthesis
  • Reduction of oxidative stress and free radical damage
  • Anti-apoptotic signaling (increased Bcl-2, decreased Bax and caspases)

In neonatal hypoxia-ischemia models, hexarelin reduced brain damage by 39%, with significant protection in the cerebral cortex, hippocampus, and thalamus.

Research Evidence

Hexarelin has been studied in both preclinical models and human clinical trials. While it never reached Phase III development, the existing research offers valuable insights into its pharmacology and potential therapeutic applications.

Growth Hormone Release Studies

Dose-Response Characteristics

A double-blind, placebo-controlled study in healthy male volunteers examined hexarelin's dose-response curve using intravenous boluses of 0.5, 1, and 2 μg/kg. Results showed:

  • Peak GH levels: 26.9 ng/mL (0.5 μg/kg), 52.3 ng/mL (1 μg/kg), and 55.0 ng/mL (2 μg/kg)
  • Time to peak: Approximately 30 minutes
  • ED₅₀: 0.48 ± 0.02 μg/kg
  • Half-life: Approximately 55 minutes

The GH response plateaued at 1 μg/kg, indicating that higher doses don't proportionally increase GH secretion but do increase the risk of side effects.

Comparison to GHRH

In head-to-head studies, hexarelin consistently outperformed GHRH. One study found hexarelin elicited a peak GH response of 62.6 μg/L compared to 19.8 μg/L with GHRH. Hexarelin also proved more resistant to metabolic suppression—glucose and free fatty acids, which normally blunt GHRH's effect, had less impact on hexarelin-induced GH release.

Multiple Routes of Administration

Hexarelin has been tested via intravenous, subcutaneous, intranasal, and oral routes:

  • IV administration: Most potent, with rapid onset and peak GH response within 30 minutes.
  • Intranasal administration: At 1.25 mg (≈18 μg/kg) three times daily, hexarelin maintained effectiveness in elderly subjects and children with short stature.
  • Oral administration: At 20 mg (≈300 μg/kg) three times daily, hexarelin stimulated GH release in elderly women, though bioavailability is low (≈0.3%) due to intestinal degradation.
  • Subcutaneous injection: Commonly used in chronic administration studies with sustained GH elevation.

Long-Term Administration and Desensitization

A 16-week study in healthy elderly individuals receiving subcutaneous hexarelin twice daily revealed partial but reversible desensitization:

  • Baseline GH response (AUC): 19.1 μg/L/hour
  • Week 16 GH response: 10.5 μg/L/hour (45% reduction)
  • Four weeks post-treatment: 19.4 μg/L/hour (full recovery)

The partial suppression of GH responsiveness did not prevent beneficial effects on body composition or growth velocity in treated children, suggesting the residual GH stimulation remained therapeutically relevant.

In vitro studies showed rapid receptor desensitization at the second messenger level, with marked reduction in calcium response occurring 2-5 minutes after initial hexarelin exposure.

Cardiovascular Research

Acute Cardiac Effects in Humans

In seven healthy male volunteers, acute intravenous hexarelin (2 μg/kg) increased left ventricular ejection fraction (LVEF) from 64.0% to 70.7% (P < 0.03) without affecting blood pressure or heart rate. In 24 male patients undergoing coronary bypass surgery, hexarelin acutely increased cardiac output and cardiac index while reducing wedge pressure.

Post-Myocardial Infarction Protection in Mice

In a mouse model of acute myocardial infarction, hexarelin treatment preserved cardiac function compared to vehicle controls:

  • Higher ejection fraction and fractional shortening at 14 days post-MI
  • Lower lung weight ratios, indicating reduced pulmonary congestion
  • Reduced cardiac fibrosis, as demonstrated by histological analysis

Mice treated with hexarelin displayed significant improvements in left ventricular function despite no difference in acute mortality rates.

Ischemia-Reperfusion Injury

In isolated rat hearts subjected to 30 minutes of ischemia followed by 120 minutes of reperfusion, hexarelin (1 μmol/L) significantly reduced infarct size. The protection was partly blocked by chelerythrine, a protein kinase C inhibitor, suggesting PKC activation contributes to hexarelin's cardioprotective effects.

Importantly, this protection occurred in hypophysectomized rats, confirming that cardiac benefits don't depend on pituitary GH secretion.

Metabolic Studies

Research in insulin-resistant MKR mice showed that chronic hexarelin treatment:

  • Improved glucose tolerance: Faster glucose clearance during glucose tolerance tests
  • Improved insulin tolerance: Better insulin sensitivity
  • Reduced triglycerides: Both plasma and hepatic triglyceride levels decreased
  • Improved body composition: Decreased fat mass, increased lean mass

These metabolic improvements occurred through CD36 and PPARγ activation, highlighting hexarelin's potential beyond GH stimulation.

In diabetic rats, hexarelin treatment also improved glucose-stimulated insulin secretion and may have protected beta cells from toxic effects, potentially through enhanced insulin sensitivity in adipose tissue.

Bone Density Research

In gonadectomized male rats (a model of osteoporosis), hexarelin (50 μg/kg subcutaneously twice daily for 30 days) completely prevented the bone mineral density loss typically seen with androgen deficiency. The effect was observed in both femoral metaphysis and lumbar vertebrae.

In ovariectomized female rats, hexarelin increased bone mineral content and bone area, with effects varying by estrogen status. Unlike GH alone, hexarelin appears to inhibit bone resorption, suggesting mechanisms beyond GH-mediated bone formation.

Neuroprotection Studies

Hippocampal Neurogenesis

In mice treated with hexarelin, the number of surviving BrdU-positive cells (newly formed neurons) in the dentate gyrus of the hippocampus significantly increased, suggesting hexarelin promotes neurogenesis and neuronal survival.

Neonatal Brain Injury

In a neonatal hypoxia-ischemia model, hexarelin reduced brain injury by 39%, with significant protection in multiple brain regions. Hexarelin altered Akt and GSK-3β phosphorylation, key signaling molecules in cell survival pathways.

Oxidative Stress Protection

In Neuro-2A cells exposed to hydrogen peroxide, hexarelin improved cell viability, maintained normal morphology, and reduced oxidative damage. It decreased caspase-3, caspase-7, and Bax (pro-apoptotic) while increasing Bcl-2 (anti-apoptotic), demonstrating robust neuroprotective signaling.

Appetite and Feeding Behavior

Unlike GHRP-6, which strongly stimulates appetite through ghrelin elevation, hexarelin's effects on feeding are more complex. Some studies report sustained appetite stimulation in both young and old rats over 8 weeks of treatment. Other research notes that hexarelin's appetite effects are less pronounced than GHRP-6, though both peptides dose-dependently stimulate feeding in satiated rats.

The appetite response may involve mechanisms independent of GH release, as some hexarelin analogs stimulate feeding without affecting GH secretion.

Comparison with Other GHRPs

Hexarelin is one of several synthetic growth hormone-releasing peptides. Understanding how it compares to GHRP-6, GHRP-2, and ipamorelin helps clarify its place in the GHRP landscape.

Hexarelin vs. GHRP-6

Hexarelin and GHRP-6 are structurally similar—the only difference is the inclusion of two methyl groups in GHRP-6. Despite this minor structural variation, their biological profiles differ:

FeatureHexarelinGHRP-6
GH PotencyHighest among GHRPsHigh, but slightly less than hexarelin
Cortisol/Prolactin ElevationYes, especially at higher dosesYes, similar to hexarelin
Appetite StimulationModerateStrong (most orexigenic GHRP)
DesensitizationRapid, pronouncedModerate
CD36 BindingYes (cardioprotective)Less characterized
Best Use CaseMaximum GH pulse or cardiac researchAppetite stimulation, wasting conditions

GHRP-6's strong appetite-stimulating properties make it better suited for research on cachexia or wasting conditions, while hexarelin's cardiac activity gives it unique utility in cardiovascular studies.

Hexarelin vs. Ipamorelin

Ipamorelin represents the opposite end of the GHRP spectrum from hexarelin: maximum selectivity versus maximum potency.

FeatureHexarelinIpamorelin
GH PotencyHighest acute GH releaseModerate GH release
SelectivityLow (affects cortisol, prolactin, appetite)Highest selectivity (GH only)
Cortisol/ProlactinElevated at higher dosesNo effect
AppetiteModerate stimulationNo effect
DesensitizationRapidMinimal
Receptor TargetsGHS-R1a, CD36GHS-R1a (selective)
Best Use CaseMaximum GH spike or cardiac researchClean GH research without confounds

Ipamorelin produces GH release without affecting ACTH, TSH, LH, FSH, prolactin, or cortisol—making it the cleanest GHRP for studies requiring isolated GH effects. Hexarelin's broader hormonal impact makes it less suitable for such research but more interesting for multi-system studies.

Hexarelin vs. GHRP-2

GHRP-2 falls between GHRP-6 and ipamorelin in terms of selectivity and potency, though it shares hexarelin's tendency to elevate cortisol and prolactin.

FeatureHexarelinGHRP-2
GH PotencyHighestHigh
Cortisol/ProlactinElevatedElevated (dose-dependent)
AppetiteModerateMinimal to none
DesensitizationRapidModerate
CD36 BindingYesNot characterized

GHRP-2 offers strong GH stimulation without the pronounced appetite effects of GHRP-6, but it lacks the cardioprotective CD36 activity that distinguishes hexarelin.

Synergy with GHRH Analogs

Hexarelin works synergistically with GHRH analogs like sermorelin, CJC-1295, and tesamorelin. When co-administered, low-dose hexarelin (0.125 μg/kg) combined with GHRH produces massive GH release—far greater than either peptide alone—with minimal effects on cortisol or prolactin. This synergy occurs because the two peptides activate complementary signaling pathways.

Comparison to Non-Peptide Secretagogues

MK-677 (ibutamoren) is a non-peptide oral GH secretagogue that also activates GHS-R1a. Unlike hexarelin, MK-677 has a much longer half-life (4-6 hours), does not desensitize receptors with chronic use, and can be taken orally with reasonable bioavailability. However, MK-677 lacks hexarelin's CD36-mediated cardioprotective effects.

Safety Profile and Side Effects

Hexarelin's safety profile reflects its potent but non-selective pharmacology. While generally well-tolerated in short-term studies, several concerns limit its therapeutic potential.

Hormonal Side Effects

Cortisol and Prolactin Elevation

Hexarelin elevates cortisol and prolactin in a dose-dependent manner. At 0.5 μg/kg IV, hexarelin causes approximately 80% increase in prolactin and 40% increase in cortisol. At lower doses, these effects are minimal, but they become more pronounced with higher doses or repeated administration.

Potential consequences:

  • Cortisol: Sleep disturbances, fat gain (especially visceral), immune suppression, mood changes (anxiety, depression)
  • Prolactin: Gynecomastia in men, galactorrhea, menstrual irregularities in women, reduced libido, potential fertility issues

Interestingly, one 16-week study found that chronic administration did not lead to sustained overstimulation of the pituitary-adrenal axis or prolactin secretion, suggesting the body may adapt to regular dosing. However, acute spikes remain a concern.

Receptor Desensitization

Hexarelin's most significant limitation is rapid receptor desensitization. In vitro, GHS receptor responses diminish within 2-5 minutes of initial exposure. In vivo, chronic use reduces GH responsiveness by approximately 45% after 16 weeks, though this effect is fully reversible after a 4-week washout period.

Implications:

  • Hexarelin requires cycling—typically 8-16 weeks on followed by 4-6 weeks off
  • Continuous use leads to diminishing returns
  • Desensitization may extend to endogenous ghrelin signaling

Cardiovascular Effects

While CD36-mediated cardiac effects are generally protective, hexarelin does increase coronary perfusion pressure in a dose-dependent manner. In individuals with compromised cardiac function or coronary artery disease, this effect warrants careful monitoring. However, clinical studies in patients undergoing bypass surgery found acute hexarelin administration improved cardiac output without adverse hemodynamic instability.

Appetite Stimulation

Hexarelin can increase appetite, particularly with sustained use. In long-term studies, it maintained a persistent appetite-stimulating effect over 8 weeks. For individuals concerned about weight gain or those with metabolic conditions, this side effect may be unwanted.

Hypoglycemia Risk

Growth hormone has complex effects on glucose metabolism. While chronic GH elevation typically promotes insulin resistance and hyperglycemia, acute GH pulses can cause transient hypoglycemia, especially in fasted states. Individuals with diabetes or those taking glucose-lowering medications should be aware of this risk.

Other Reported Side Effects

In clinical studies and anecdotal reports, additional side effects include:

  • Water retention and mild edema (GH-mediated)
  • Joint pain or carpal tunnel-like symptoms (with prolonged use)
  • Headache
  • Dizziness or lightheadedness
  • Injection site reactions (subcutaneous administration)
  • Possible impact on thyroid function (though not consistently reported)

Long-Term Safety Unknowns

Hexarelin never completed Phase III trials, meaning long-term safety data in humans is limited. Concerns that contributed to its discontinued development include:

  • Potential for sustained alterations in hormonal axes
  • Unknown cancer risk (GH's relationship to cancer is complex and debated)
  • Long-term cardiovascular effects of CD36 modulation
  • Effects on metabolic health with extended use

Contraindications and Precautions

Hexarelin should be avoided or used with extreme caution in:

  • Active cancer or history of malignancy (GH may promote tumor growth)
  • Diabetic retinopathy (GH can worsen retinal complications)
  • Uncontrolled diabetes
  • Acute critical illness
  • Pregnancy and breastfeeding (no safety data)
  • Children and adolescents (except under controlled research protocols)

Hexarelin occupies a complex legal and regulatory landscape. While it has been extensively researched, it lacks approval for human therapeutic use in any jurisdiction.

FDA Status

Hexarelin is not approved by the FDA for human use. It progressed through Phase I and Phase II clinical trials in the 1990s for growth hormone deficiency and heart failure but did not advance to Phase III. As of 2024, no pharmaceutical company has brought hexarelin to market as a therapeutic drug.

In May 2007, the FDA granted orphan drug designation to ARD-07, a peptidomimetic analog of hexarelin, for diagnostic use in growth hormone deficiency. This designation applies only to the specific analog for diagnostic purposes—not hexarelin itself for therapeutic applications.

Hexarelin cannot be prescribed by physicians and cannot be compounded by pharmacies for human use. It is legal to purchase and use hexarelin only as a research chemical for in vitro studies or animal research conducted under appropriate institutional oversight.

WADA Prohibited Status

The World Anti-Doping Agency (WADA) classifies hexarelin as a prohibited substance under Category S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. This category includes all growth hormone-releasing peptides, including GHRP-1, GHRP-2, GHRP-6, and hexarelin.

Hexarelin is banned at all times—both in-competition and out-of-competition—for athletes subject to WADA jurisdiction. Violating this prohibition can result in suspensions, disqualification, and forfeiture of results.

The rationale for prohibition is twofold:

  1. Performance enhancement: GH promotes muscle growth, fat loss, and recovery—effects that confer competitive advantages.
  2. Health risk: Chronic supraphysiological GH levels carry metabolic and cardiovascular risks.

International Regulatory Status

Hexarelin's legal status varies by country, but it remains largely unavailable for human therapeutic use worldwide:

  • United States: Not approved; available only for research
  • European Union: Not approved by the European Medicines Agency (EMA)
  • Canada: Not approved by Health Canada
  • Australia: Listed as a prohibited import under Therapeutic Goods Administration (TGA) regulations

Veterinary Use

There is limited documented use of hexarelin in veterinary medicine. While some peptides like BPC-157 have found experimental veterinary applications, hexarelin's rapid desensitization and hormonal side effects make it less practical for animal use.

Research and Academic Use

Hexarelin remains available from chemical suppliers for non-human research purposes. Scientists studying growth hormone physiology, cardiac protection, or metabolic regulation can legally obtain hexarelin for in vitro or animal studies under institutional review board (IRB) or institutional animal care and use committee (IACUC) approval.

Compounding Pharmacy Crackdown

In recent years, the FDA has increased enforcement against compounding pharmacies that manufacture and distribute unapproved peptides like hexarelin, semaglutide (off-label compounding), and other investigational compounds. Clinics and providers prescribing hexarelin for "anti-aging" or "wellness" purposes operate in a legal gray area and risk regulatory action.

Individuals purchasing hexarelin outside of approved research contexts may face legal consequences, particularly if the substance is imported or purchased without proper documentation. Possession of hexarelin without legitimate research justification could be interpreted as intent to use for performance enhancement or other unapproved purposes, potentially violating anti-doping regulations or controlled substance laws depending on jurisdiction.

Frequently Asked Questions

What is hexarelin used for?

Hexarelin is a research peptide studied for its ability to stimulate growth hormone release and provide cardioprotective effects. While it was evaluated in clinical trials for growth hormone deficiency and heart failure, it was never approved for therapeutic use. Today, hexarelin is used exclusively in research settings to study GH physiology, cardiac protection, and metabolic regulation. It is not legally available for human use outside controlled research.

How does hexarelin differ from other GHRPs like GHRP-6 or ipamorelin?

Hexarelin is the most potent GHRP in terms of acute GH release, producing GH pulses up to three times larger than GHRH. However, it also causes rapid receptor desensitization, elevates cortisol and prolactin at higher doses, and has moderate appetite-stimulating effects. GHRP-6 is similarly potent but causes stronger appetite stimulation. Ipamorelin is the most selective GHRP—it stimulates GH without affecting cortisol, prolactin, or appetite, but its GH-releasing potency is lower than hexarelin. Hexarelin is also unique for binding to the CD36 scavenger receptor, giving it cardioprotective properties independent of GH.

Does hexarelin desensitize receptors?

Yes, hexarelin causes rapid receptor desensitization—the fastest among all GHRPs. In vitro studies show that GHS receptor signaling diminishes within 2-5 minutes of exposure. In human studies, chronic twice-daily administration for 16 weeks reduced GH responsiveness by approximately 45%, though responsiveness fully recovered after a 4-week washout period. To minimize desensitization, hexarelin protocols typically involve cycling—8 to 16 weeks on followed by 4 to 6 weeks off.

What are the side effects of hexarelin?

The most common side effects include cortisol and prolactin elevation (especially at higher doses), appetite stimulation, water retention, and headache. Cortisol elevation can lead to sleep disturbances, fat gain, immune suppression, and mood changes. Elevated prolactin may cause gynecomastia, reduced libido, and fertility issues. Receptor desensitization is another key limitation—continuous use leads to diminishing effectiveness. Hexarelin should be avoided in individuals with active cancer, uncontrolled diabetes, or acute critical illness.

Hexarelin is not approved by the FDA or any regulatory agency for human therapeutic use. It is legal to purchase as a research chemical for in vitro or animal studies but cannot be legally prescribed, dispensed, or used in humans outside of approved clinical trials. The World Anti-Doping Agency (WADA) classifies hexarelin as a prohibited substance, banning its use at all times for athletes. Purchasing or using hexarelin for personal use, performance enhancement, or anti-aging purposes may carry legal risks depending on jurisdiction.

How is hexarelin administered?

In research settings, hexarelin has been administered via intravenous injection, subcutaneous injection, intranasal spray, and oral capsules. Intravenous administration produces the most rapid and potent GH response. Subcutaneous injection is commonly used for chronic studies. Intranasal administration has been tested in children and elderly subjects with sustained effectiveness. Oral administration has very low bioavailability (approximately 0.3%) due to peptide degradation in the gastrointestinal tract, requiring much higher doses to achieve effects.

Does hexarelin help with fat loss or muscle growth?

Hexarelin's potent GH-releasing effects theoretically support fat loss and muscle growth, as GH promotes lipolysis (fat breakdown) and stimulates IGF-1 production, which drives muscle protein synthesis. Animal studies and limited human data suggest favorable changes in body composition—reduced fat mass and increased lean mass. However, these effects are indirect (mediated through GH and IGF-1) and are accompanied by rapid receptor desensitization, limiting long-term effectiveness. More selective GH interventions or compounds like MK-677 may offer more sustained benefits for body composition.

Can hexarelin protect the heart?

Yes, hexarelin has demonstrated cardioprotective effects in preclinical research. It binds to the CD36 scavenger receptor in cardiac tissue, independent of GH release. Studies show that hexarelin reduces infarct size following myocardial ischemia, prevents cardiomyocyte apoptosis, improves left ventricular function post-heart attack, and increases coronary perfusion. In human studies, acute hexarelin administration increased ejection fraction in healthy volunteers and improved cardiac output in patients undergoing bypass surgery. However, these findings come from small, early-stage studies. Hexarelin's cardiac benefits remain a research focus and have not been validated in large-scale clinical trials.

What is the CD36 receptor and why does it matter?

CD36 is a scavenger receptor found on cardiomyocytes, endothelial cells, macrophages, and adipocytes. It plays roles in fatty acid uptake, lipid metabolism, inflammation, and cardiovascular function. Hexarelin binds to CD36 in cardiac tissue, triggering protective signaling pathways that reduce ischemia-reperfusion injury, inhibit apoptosis, and improve cardiac function—effects that occur even in the absence of GH. This dual-receptor activity (GHS-R1a for GH release and CD36 for cardiac protection) makes hexarelin unique among GHRPs and has shifted research interest toward its cardiovascular applications.

Bottom Line

Hexarelin is the most potent growth hormone-releasing peptide ever developed, capable of triggering GH pulses that exceed those from GHRH by threefold. But potency alone doesn't tell the full story. Its rapid receptor desensitization, cortisol and prolactin elevation, and complex multi-system effects make it a challenging compound for therapeutic development—challenges that ultimately stalled its clinical progression.

What keeps hexarelin relevant in research is its unique dual-receptor activity. Beyond the ghrelin receptor, hexarelin binds to CD36, a scavenger receptor in cardiac tissue, conferring cardioprotective effects that work independently of growth hormone. This discovery shifted research focus from endocrinology to cardiology, where hexarelin continues to offer insights into ischemia-reperfusion injury, heart failure, and cardiac remodeling.

For those researching growth hormone physiology, hexarelin remains a valuable tool for understanding the limits of GH stimulation, the mechanisms of receptor desensitization, and the interplay between GH secretagogues and metabolic regulation. But for practical applications—whether clinical or investigational—more selective, sustainable options like ipamorelin, CJC-1295, or MK-677 offer better long-term profiles without hexarelin's rapid tolerance.

Hexarelin is not approved for human use, remains prohibited by WADA, and carries hormonal side effects that require careful management. Its story is one of scientific intrigue—a peptide that revealed unexpected biology, opened new research directions, but ultimately proved too complex for the clinic. For researchers, clinicians, and curious readers, hexarelin represents both the promise and limitations of synthetic peptide pharmacology.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Hexarelin is not approved by the FDA for human therapeutic use and is prohibited by the World Anti-Doping Agency for athletic use. Do not use hexarelin or any unapproved peptide without supervision from a qualified healthcare provider in an approved research or clinical setting. PeptideJournal.org does not sell peptides or endorse their use outside of legal, regulated contexts.

References

  1. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PubMed

  2. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-460. PubMed

  3. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf). 1995;43(5):631-635. PubMed

  4. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. 1998;83(5):1644-1649. PubMed | Full Text

  5. Ghigo E, Arvat E, Gianotti L, et al. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-425. PubMed

  6. Muccioli G, Broglio F, Valetto MR, et al. Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris). 2000;61(1):27-31. PubMed

  7. Bodart V, Bouchard JF, McNicoll N, et al. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res. 1999;85(9):796-802. PubMed

  8. Demers A, McNicoll N, Febbraio M, et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J. 2004;382(Pt 2):417-424. PubMed | PMC Full Text

  9. Tivesten A, Bollano E, Caidahl K, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology. 2000;141(1):60-66. PubMed

  10. Rossoni G, Muscari C, Bonomo C, et al. Cardiac anti-ischaemic and antiarrhythmic effects of the growth hormone-releasing peptide Hexarelin. Eur J Pharmacol. 2004;484(2-3):137-145. PubMed

  11. Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. PubMed | Full Text

  12. Xu X, Bong AHL, Lu L, et al. One dose of oral hexarelin protects chronic cardiac function after myocardial infarction. Peptides. 2014;56:156-162. PubMed | Full Text

  13. Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014;11(3):253-258. PubMed | PMC Full Text

  14. Barreiro ML, Suominen JS, Dávila N, et al. Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Peptides. 2018;103:51-59. PMC Full Text

  15. Xu L, Gao Y, Lau YS, et al. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology. 2017;158(10):3174-3187. PubMed | PMC Full Text

  16. Kim MS, Yoon CY, Park KH, et al. Enhanced Pulsatile Growth Hormone Secretion and Altered Metabolic Hormones by in Vivo Hexarelin Treatment in Streptozotocin-Induced Diabetic Rats. Front Endocrinol (Lausanne). 2018;9:652. PMC Full Text

  17. Granata R, Settanni F, Biancone L, et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-Kinase/Akt signaling. Endocrinology. 2007;148(2):512-529. PubMed

  18. Cordido F, Peñalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 1993;76(4):819-823. PubMed

  19. Penalva A, Pombo M, Carballo A, et al. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin Endocrinol (Oxf). 1993;38(1):87-91. PubMed

  20. Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 1994;54(18):1321-1328. PubMed

  21. Locatelli V, Torsello A, Redaelli M, Ghigo E, Massara F, Muller EE. Hexarelin, a synthetic growth hormone-releasing peptide, is a powerful stimulus of growth hormone gene expression and release in the growth hormone-releasing hormone-deprived infant rat. Pediatr Res. 1995;38(3):323-328. PubMed

  22. Massoud AF, Hindmarsh PC, Matthews DR, Brook CG. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity. Clin Endocrinol (Oxf). 1996;44(5):555-562. PubMed

  23. Arvat E, Broglio F, Aimaretti G, et al. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest. 2000;23(8):493-495. PubMed

  24. Arvat E, Ceda GP, Di Vito L, et al. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging. Pituitary. 1998;1(1):51-58. PubMed

  25. Micic D, Popovic V, Kendereski A, et al. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clin Endocrinol (Oxf). 1995;42(2):191-194. PubMed

  26. Broglio F, Benso A, Gottero C, et al. Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans. J Endocrinol Invest. 2003;26(3):192-196. PubMed

  27. Arvat E, Di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891. PubMed

  28. Arvat E, Maccagno B, Giordano R, et al. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. Eur J Endocrinol. 1997;136(2):165-169. PubMed

  29. Bellone S, Bartolotta E, Cardinale G, et al. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Eur J Endocrinol. 1999;140(5):398-401. PubMed

  30. Gianotti L, Rolla M, Arvat E, et al. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with Cushing's disease. J Endocrinol Invest. 1997;20(4):174-179. PubMed

  31. Alvarez CV, Zalvide J, Señaris RM, Casanueva FF, Dieguez C. Mechanism of action of hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat. Neuroendocrinology. 1994;59(6):582-589. PubMed

  32. Conti E, Andreotti F, Sestito A, et al. Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am J Cardiol. 2002;89(8):973-975. PubMed

  33. Napoli R, Guardasole V, Matarazzo M, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol. 2002;39(1):90-95. PubMed

  34. Bisi G, Podio V, Valetto MR, et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol. 1999;381(1):31-38. PubMed

  35. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-1469. PubMed

  36. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. PubMed

  37. Higham CE, Trainer PJ. Growth hormone excess and the development of growth hormone receptor antagonists. Exp Physiol. 2008;93(11):1157-1169. PubMed

  38. Kopchick JJ, List EO, Kelder B, Gosney ES, Berryman DE. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications. Mol Cell Endocrinol. 2014;386(1-2):34-45. PubMed

  39. Devesa J, Almengló C, Devesa P. Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth? Clin Med Insights Endocrinol Diabetes. 2016;9:47-71. PMC Full Text

  40. Strobl JS, Thomas MJ. Human growth hormone. Pharmacol Rev. 1994;46(1):1-34. PubMed

  41. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15(1):80-101. PubMed

  42. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000;85(12):4908-4911. PubMed

  43. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86(12):5992. PubMed

  44. Nass R, Farhy LS, Liu J, et al. Evidence for acyl-ghrelin modulation of growth hormone release in the fed state. J Clin Endocrinol Metab. 2008;93(5):1988-1994. PubMed

  45. McCall GE, Byrnes WC, Dickinson A, Pattany PM, Fleck SJ. Muscle fiber hypertrophy, hyperplasia, and capillary density in college men after resistance training. J Appl Physiol. 1996;81(5):2004-2012. PubMed

  46. Doessing S, Heinemeier KM, Holm L, et al. Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. J Physiol. 2010;588(Pt 2):341-351. PMC Full Text

  47. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999;96(13):7324-7329. PMC Full Text

  48. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-369. PubMed

  49. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PMC Full Text

  50. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. PubMed